Everstone Group to invest up to $50 mln in Slayback Pharma

The Everstone Group has agreed to invest up to $50 million in Series B funding in Slayback Pharma.

The Everstone Group has agreed to invest up to $50 million in Series B funding in Slayback Pharma. New Jersey-based Slayback is focused on generic and specialty pharmaceutical products.

Source: Press Release